BostonGene’s Foundation Model of Cancer and the Immune System–Led Approach Recognized for Advancing Precision Oncology and De-Risking Drug Development for Biopharma

WALTHAM, Mass.: BostonGene, developer of the leading AI foundational model for cancer and the immune system, announced today it has been recognized with multiple honors at the 2025 Stevie® Awards for Technology Excellence. The wins underscore BostonGene’s position as a critical driver of oncology drug development-delivering the multiomic intelligence and AI-powered analytics pharmaceutical companies need to de-risk development, accelerate trial timelines and capture key market segments.

BostonGene earned two Gold Stevie Awards and three Silver Stevie Awards across several categories:

Gold Stevie® Winners

• Biomarker Discovery Platform - Technical Innovation of the Year – Biotechnology
• Target Analysis Solution - Technology Breakthrough of the Year – Biotechnology

Silver Stevie® Winners

• End-to-End Drug Repurposing Solutions -New Product of the Year – Healthcare Technology
• Biomarker Discovery Platform - Technical Innovation of the Year – Healthcare Technology
• Target Analysis Solution - Technology Breakthrough of the Year – Healthcare Technology

“We are honored to receive multiple Stevie Awards recognizing our platform’s transformative impact on oncology R&D,” said Andrew Feinberg, President and CEO of BostonGene. “These accolades validate the value we bring to pharma by delivering clinically actionable insights that reduce trial risk, increase regulatory success and ultimately improve patient outcomes.”

Biomarker Discovery Platform
BostonGene’s biomarker discovery platform uses AI-driven, multiomic analytics that integrate whole exome sequencing (WES), whole transcriptome sequencing (WTS), circulating tumor DNA (ctDNA), flow cytometry and spatial proteomics. The platform identifies biomarkers predictive of therapeutic response and resistance across diverse cancer types. By delivering robust, clinically relevant biomarker insights, it supports smarter trial design, precise patient stratification and improves clinical development.

Target Analysis Solution
BostonGene’s target analysis solution enables the development of antibody–drug conjugates (ADCs), bispecific antibodies and other targeted therapies through tumor- and indication-specific target identification and prioritization. Using a proprietary database of 100,000+ transcriptomic profiles, the platform distinguishes target expression between tumor cells, the tumor microenvironment and normal tissues. This approach provides high-confidence target validation, reduces off-target risk and informs strategic label expansion and combination therapy planning.

End-to-End Drug Repurposing Solutions
BostonGene’s drug repurposing solution offers a data-driven approach to indication expansion by integrating AI-powered molecular profiling, curated clinical literature and comprehensive drug databases. The platform evaluates 7,000+ anti-cancer agents, 30,000+ publications and 10,000+ clinical trials to identify unmet clinical needs, competitive gaps and high-probability, low-risk opportunities for repurposing. The approach reduces cost, timelines and risk-delivering a clear competitive advantage for biopharma innovators.

About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.

About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Fonte: Business Wire